Evaluation and Management of Hematuria in Adults

Diagnostic Approach

The American Urological Association recommends a complete urologic evaluation for men over 40 years old with hematuria, as the cancer risk is age-dependent, not timing-dependent 1
Urinalysis with microscopy is essential to confirm hematuria and assess for red cell casts or dysmorphic RBCs that would suggest glomerular disease rather than urologic malignancy 1
Urine cytology is recommended to detect high-grade transitional cell carcinoma and carcinoma in situ 1
Serum creatinine is necessary to assess renal function and identify potential renal parenchymal disease 1
Digital rectal examination (DRE) is crucial to assess prostate size and tenderness 2, 3

Smoking history is the most critical risk factor for bladder cancer 1
Occupational exposures to benzenes, aromatic amines, chemicals, or dyes increase the risk of bladder cancer 1
History of gross hematuria episodes is a significant risk factor for bladder cancer 1

Cystoscopy is mandatory for all patients over 40 years with hematuria, even if upper tract imaging reveals a benign source like an enlarged prostate 1
Flexible cystoscopy under local anesthesia is preferred due to lower pain, fewer post-procedure symptoms, and equivalent or superior diagnostic accuracy 1
CT urography is the best imaging modality for evaluating the upper urinary tract, optimally detecting urinary stones, renal masses, and associated complications 1

Fluid management, avoiding bladder irritants, and encouraging physical activity are recommended as initial conservative management for lower urinary tract symptoms 2
Alpha-blockers (tamsulosin 0.4 mg once daily) are recommended as first-line pharmacologic therapy for lower urinary tract symptoms 2
5α-reductase inhibitors (finasteride 5 mg daily) are recommended for men with enlarged prostates (>40-50 cc) 2

Surveillance is critical because hematuria can precede cancer diagnosis by years, and repeat urinalysis, urine cytology, and blood pressure should be performed at 6, 12, 24, and 36 months 1
Evaluation 4-12 weeks after initiating treatment is necessary to assess response using standardized questionnaires like the International Prostate Symptom Score (IPSS) 2
Annual follow-up is recommended for successful treatment to detect symptom progression or complications 2

The American Urological Association recommends that patients with gross hematuria undergo urgent urologic referral for comprehensive evaluation, regardless of other findings 4, 5
PVR measurement should be repeated 2-3 times to confirm the finding, as marked intra-individual variability may occur 4
In patients with hematuria, malignancy must be excluded first, even if symptoms suggest possible bladder outlet obstruction from benign prostatic hyperplasia 4, 5

Serum PSA should be obtained if life expectancy is >10 years, as it can help predict prostate volume and guide treatment planning 4, 5
Uroflowmetry with at least 2 measurements (ideally with voided volumes >150 mL) should be performed to assess flow patterns, with Qmax <10 mL/second indicating significant obstruction 4, 5
Pressure-flow urodynamic studies should be conducted if Qmax >10 mL/second to distinguish detrusor underactivity from bladder outlet obstruction before any invasive therapy 4, 5
Upper urinary tract imaging is specifically indicated in patients with hematuria to evaluate for malignancy 4, 5